CVE-2026-24217
CVE-2026-24217 is a high-severity vulnerability in Nvidia Bionemo Framework with a CVSS 3.x base score of 8.8. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-29.
Key facts
- Severity: High (CVSS 3.x base score 8.8)
- EPSS exploit prediction: 1% (51st percentile)
- Actively exploited: Not listed in CISA KEV
- EU (EUVD) id: EUVD-2026-31144
- Weakness: CWE-29
- Affected product: Nvidia Bionemo Framework
- Published:
- Last modified:
Description
NVIDIA BioNeMo Core for Linux contains a vulnerability where a user could cause a path traversal by loading a malicious file. A successful exploit of this vulnerability might lead to code execution, denial of service, information disclosure, and data tampering.
Frequently asked questions
- What is CVE-2026-24217?
- NVIDIA BioNeMo Core for Linux contains a vulnerability where a user could cause a path traversal by loading a malicious file. A successful exploit of this vulnerability might lead to code execution, denial of service, information disclosure, and data tampering.
- How severe is CVE-2026-24217?
- CVE-2026-24217 has a CVSS 3.x base score of 8.8, rated high severity. It is exploitable over network with low attack complexity, requires no privileges and user interaction. Impact on confidentiality is high, integrity high, and availability high.
- Is CVE-2026-24217 being actively exploited?
- It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 1% (51st percentile), an estimate of the probability of exploitation in the next 30 days.
- What products are affected by CVE-2026-24217?
- CVE-2026-24217 affects Nvidia Bionemo Framework. See the affected-products list for the exact vulnerable versions.
- How do I fix CVE-2026-24217?
- Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.
- Does CVE-2026-24217 have an EU (EUVD) identifier?
- Yes. CVE-2026-24217 is tracked in the ENISA EU Vulnerability Database (EUVD) as EUVD-2026-31144.
- When was CVE-2026-24217 published?
- CVE-2026-24217 was published on 2026-05-20 and last updated on 2026-06-17.
References
- https://nvd.nist.gov/vuln/detail/CVE-2026-24217
- https://nvidia.custhelp.com/app/answers/detail/a_id/5831
- https://www.cve.org/CVERecord?id=CVE-2026-24217
Affected products (1)
- cpe:2.3:a:nvidia:bionemo_framework:*:*:*:*:*:*:*:*
More vulnerabilities in Nvidia Bionemo Framework
- CVE-2026-24164 — High (CVSS 8.8): NVIDIA BioNeMo contains a vulnerability where a user could cause a deserialization of untrusted data. A successful…
- CVE-2026-24216 — High (CVSS 7.8): NVIDIA BioNemo for Linux contains a vulnerability where a user could cause a deserialization of untrusted data. A…
- CVE-2026-24165 — High (CVSS 7.8): NVIDIA BioNeMo contains a vulnerability where a user could cause a deserialization of untrusted data. A successful…
All CVEs affecting Nvidia Bionemo Framework →
Other CWE-29 vulnerabilities
- CVE-2025-15036 — Critical (CVSS 10.0): A path traversal vulnerability exists in the `extract_archive_to_dir` function within the…
- CVE-2024-2083 — Critical (CVSS 9.9): A directory traversal vulnerability exists in the zenml-io/zenml repository, specifically within the /api/v1/steps…
- CVE-2024-6396 — Critical (CVSS 9.8): A vulnerability in the `_backup_run` function in aimhubio/aim version 3.19.3 allows remote attackers to overwrite any…
- CVE-2024-5443 — Critical (CVSS 9.8): CVE-2024-4320 describes a vulnerability in the parisneo/lollms software, specifically within the…
- CVE-2024-2358 — Critical (CVSS 9.8): A path traversal vulnerability in the '/apply_settings' endpoint of parisneo/lollms-webui allows attackers to execute…
- CVE-2023-6975 — Critical (CVSS 9.8): A malicious user could use this issue to get command execution on the vulnerable machine and get access to data &…